Vertex Pharmaceuticals (VRTX) Scheduled to Post Quarterly Earnings on Monday

Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing its earnings results after the market closes on Monday, November 4th. Analysts expect the company to announce earnings of $3.60 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing the consensus estimate of ($12.54) by ($0.29). The company had revenue of $2.65 billion for the quarter, compared to analysts’ expectations of $2.66 billion. Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. The company’s revenue was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.53 earnings per share. On average, analysts expect Vertex Pharmaceuticals to post $-2 EPS for the current fiscal year and $16 EPS for the next fiscal year.

Vertex Pharmaceuticals Price Performance

VRTX opened at $471.12 on Friday. The stock has a fifty day moving average price of $474.53 and a 200 day moving average price of $464.46. The company has a current ratio of 2.52, a quick ratio of 2.26 and a debt-to-equity ratio of 0.02. Vertex Pharmaceuticals has a 1 year low of $341.90 and a 1 year high of $510.64. The stock has a market cap of $121.60 billion, a price-to-earnings ratio of -232.08 and a beta of 0.40.

Analyst Ratings Changes

Several equities research analysts recently commented on VRTX shares. StockNews.com cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, August 5th. Bank of America dropped their price target on shares of Vertex Pharmaceuticals from $550.00 to $541.00 and set a “buy” rating on the stock in a research note on Monday, October 14th. Royal Bank of Canada reduced their price objective on shares of Vertex Pharmaceuticals from $431.00 to $425.00 and set a “sector perform” rating for the company in a research note on Friday, October 4th. Morgan Stanley increased their target price on shares of Vertex Pharmaceuticals from $462.00 to $474.00 and gave the stock an “equal weight” rating in a research report on Tuesday, October 1st. Finally, TD Cowen boosted their price target on Vertex Pharmaceuticals from $450.00 to $500.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Hold” and an average price target of $492.50.

Insider Activity at Vertex Pharmaceuticals

In related news, CMO Carmen Bozic sold 2,280 shares of the company’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $476.75, for a total value of $1,086,990.00. Following the completion of the transaction, the chief marketing officer now directly owns 23,259 shares in the company, valued at approximately $11,088,728.25. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Chairman Jeffrey M. Leiden sold 3,784 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $499.00, for a total value of $1,888,216.00. Following the sale, the chairman now owns 9,994 shares of the company’s stock, valued at approximately $4,987,006. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $476.75, for a total value of $1,086,990.00. Following the completion of the transaction, the chief marketing officer now owns 23,259 shares of the company’s stock, valued at approximately $11,088,728.25. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,710 shares of company stock worth $3,298,206 over the last three months. Company insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.